Feature | January 29, 2013

Transparent Pricing Does Not Curb Doctors’ Use of High-Cost Hospital Imaging Tests

MRI, CT Systems Imaging Transparent Pricing Study

January 29, 2013 — In a study designed to see if doctors who are told the exact price of expensive medical tests like magnetic resonance imaging (MRI) in advance would order fewer of them, Johns Hopkins researchers got their answer: No.

In a report published online in the Journal of the American College of Radiology, the researchers found that revealing the costs of MRIs and other imaging tests up front had no impact on the number of tests doctors ordered for their hospitalized patients.

“Cost alone does not seem to be the determining factor in deciding to go ahead with an expensive radiographic test,” says the study’s senior author, Daniel J. Brotman, M.D., an associate professor of medicine at the Johns Hopkins University School of Medicine and director of the hospitalist program at The Johns Hopkins Hospital. “There is definitely an over-ordering of tests in this country, and we can make better decisions about whether our patients truly need each test we order for them. But when it comes to big-ticket tests like MRI, it appears the doctors have already decided they need to know the information, regardless of the cost of the test.”

Studies in the past suggest that much of the expense of laboratory tests, medical imaging and prescription drugs is unknown or hidden from providers and patients at the time of ordering, leaving financial considerations largely out of the health care decision-making process and likely driving up costs, Brotman notes.

Other studies have shown that doctors ordered fewer laboratory tests in some cases when they were given the price up front. But Brotman says imaging tests appear to be “a different animal.”

There are built-in disincentives to ordering many major tests if they are not necessary, such as the potential danger of radiation used in some, Brotman says. In addition to making physicians more sensitive to the costliness of unnecessary testing, Brotman says they need to learn how to explain to patients why they may not need them.

For the study, Brotman and his colleagues identified the 10 imaging tests most frequently ordered for patients at The Johns Hopkins Hospital. Dividing the tests into two groups, they made sure prices were attached to one group over a six-month period, from November 2009 to May 2010. Brotman and his colleagues left out the pricing information for the other group over the same time period. Prices are not typically shared with physicians or patients in most medical settings.

When the researchers compared the ordering rates to the rates from a six-month period a year earlier, when no costs were displayed at all, they found no significant difference in ordering patterns.

Brotman says he might have been concerned if there was a large decrease in ordering expensive tests, as there are many instances when the expensive test is justified. For example, when a patient appears to have had a sub-acute stroke, an MRI is often justified “regardless of cost,” he says. “When a key diagnosis is needed in imaging, there are limited options for comparison shopping.”

That is not to say there are not times when physicians need to look more closely at whether too many imaging tests are being ordered, Brotman says. For example, patients in a hospital intensive care unit who are on a ventilator and unable to tell doctors how they are feeling may not need a daily chest X-ray to scan for potential problems. Brotman says there is evidence that outcomes are not compromised if X-rays are ordered only when the patient’s condition appears to be worsening. MRIs are also ordered too frequently for lower back pain, he says.

“For too long, there has not been enough attention paid to the bottom line in health care,” Brotman says. This is not about rationing care to hold down costs, he says, but about choosing tests a little more wisely. “There are financial consequences for the choices we make, and for too long we haven’t considered them,” he says.

Even though price transparency did not influence the way physicians ordered imaging tests in his study, Brotman says financial considerations may play a role in other circumstances if tied to clinical evidence.

For example, he says, when clinical programs began to compare the amount of blood products used by surgeons, those who were using far more than their peers (and with similar patient outcomes) took note and reduced their reliance on transfusions, which are not only costly but also carry risks.

If you show a provider that he or she is ordering four times as many computed tomography (CT) scans as a colleague whose patients have similar outcomes, it could change the decision-making calculus for the better, he says.

“Cost transparency must be part of the solution to solving fiscal challenges in medicine,” Brotman says. “Providers have no idea how much they’re spending. Patients don’t know either. Having everyone understand more of the economics of health care is a great place to start cutting costs in medicine.”

The study was supported, in part, by the Research and Education Foundation of the Radiological Society of North America, the Walter and Mary Ciceric Research Award and the Johns Hopkins Hospitalist Scholars Program.

Other Johns Hopkins researchers involved in the study include Daniel J. Durand, M.D.; Leonard S. Feldman, M.D.; and Jonathan S. Lewin, M.D.

For more information: www.hopkinsmedicine.org/gim/faculty/brotman.html

Related Content

Toshiba Showcases Vantage Galan 3T MRI at ISMRM 2017
News | Magnetic Resonance Imaging (MRI)| April 24, 2017
April 24, 2017 — Offering a full range of advanced clinical applications for researchers, Toshiba Medical will demons
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...

Physicians will need to use a CMS-certified appropriate use criteria (AUC) clinical decision support software that documents the appropriateness of an imaging order to receive full reimbursement for Medicare patients starting Jan. 1, 2018.

Feature | Cardiac Imaging| April 18, 2017 | Dave Fornell
As part of U.S. healthcare reform efforts, starting Jan.
University of California Study Searches for Consistent CT Dose Best Practices
News | Radiation Dose Management| April 17, 2017
A new study led by UC San Francisco has found that radiation doses can be safely and effectively reduced – and more...
cardiac CT showing a severe right coronary artery lesion on a Toshiba Aquillion One

A cardiac CT showing a severe right coronary artery lesion on both 3-D and curved multiplanar reconstructions from a Toshiba Aquilion One CT system. The newest generation of CT scanners have very fast gantry speeds to freeze cardiac motion, improved image quality and much lower doses than previous generation scanners from a decade ago.

Feature | CT Angiography (CTA)| April 13, 2017 | Dave Fornell
Cardiac computed tomography (CT) imaging really took off a decade ago with the introduction of 64-slice scanners, whi
Toshiba Medical Launches Aquilion Lightning CT System
News | Computed Tomography (CT)| April 12, 2017
April 12, 2017 — Providers can now offer enhanced care and safe imaging to patients with a compact and economical sol
FDA Clears Siemens Somatom go. CT platform
Technology | Computed Tomography (CT)| April 11, 2017
The U.S. Food and Drug Administration (FDA) has cleared the Somatom go. computed tomography (CT) platform from Siemens...
SCCT, Toshiba Medical, partnership, residents-in-training
News | Computed Tomography (CT)| April 05, 2017
The Society of Cardiovascular Computed Tomography (SCCT) and Toshiba Medical announced a new partnership dedicated to...
Toshiba, Aquilion One CT, model-based iterative reconstruction, MBIR, ACC 2017, FIRST, RSNA 2017
News | Computed Tomography (CT)| March 21, 2017
March 21, 2017 — Toshiba Medical demonstrated its Forward projected model-based Iterative Reconstruction SoluTion (FI
RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology| March 21, 2017
March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clo
Overlay Init